Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
IrelandIPO:
21 October 1992Website:
http://www.trinitybiotech.comNext earnings report:
03 October 2024Last dividends:
05 June 2015Next dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
TRIB Latest News
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to advance its next generation continuous glucose monitoring (“CGM”) solution towards market launch. Since acquiring the CGM technology earlier in the year, Trinity Biotech has been working on further innovations and improvements to the original device. The Company has now received regulatory approval to conduct its initial European pre-pivotal trial that will inform the larger pivotal trial that will be required for product registration and launch.
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024.
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring (“CGM”) microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM biosensor technology and artificial intelligence (“AI”) driven health & wellness analytics platform, as well as providing additional visibility on the international commercialisation of these solutions.
Trinity Biotech plc (NASDAQ:TRIB ) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Operator Greetings, and welcome to the Trinity Biotech First Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET. Conference Call Dial-In & Webcast Information Date: Thursday, May 23, 2024 Time: 8:30 AM ET United States: 1-877-407-0784 International: 1- 201-689-8560 Conference ID: Webcast:Call me™: 13746798 webcast link https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 About Trinity Biotech Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors.
Trinity Biotech plc (NASDAQ:TRIB ) Q4 2023 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Eric Ribner - Investor Relations Conference Call Participants Jim Sidoti - Sidoti & Company Paul Nouri - Noble Operator Greetings! Welcome to the Trinity Biotech's Fourth Quarter and Full Year 2023 Earnings Conference Call.
DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET. Conference Call Dial-In & Webcast Information Date: Thursday, April 4, 2024 Time: 8:00 AM ET United States: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13745604 Call me™: https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 Webcast Click here for webcast About Trinity Biotech Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market.
Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.
Trinity Biotech plc (TRIB) Acquisition of the CGM Assets of Waveform Technologies and Q3 2023 Earnings Call (Transcript)
DUBLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2023 on Tuesday, October 3, 2023.
What type of business is Trinity Biotech?
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
What sector is Trinity Biotech in?
Trinity Biotech is in the Healthcare sector
What industry is Trinity Biotech in?
Trinity Biotech is in the Medical Devices industry
What country is Trinity Biotech from?
Trinity Biotech is headquartered in Ireland
When did Trinity Biotech go public?
Trinity Biotech initial public offering (IPO) was on 21 October 1992
What is Trinity Biotech website?
https://www.trinitybiotech.com
Is Trinity Biotech in the S&P 500?
No, Trinity Biotech is not included in the S&P 500 index
Is Trinity Biotech in the NASDAQ 100?
No, Trinity Biotech is not included in the NASDAQ 100 index
Is Trinity Biotech in the Dow Jones?
No, Trinity Biotech is not included in the Dow Jones index
When does Trinity Biotech report earnings?
The next expected earnings date for Trinity Biotech is 03 October 2024